mHSPC VL

Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression....

Real-World Treatment Trends in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata

Details
Alicia Morgans and Pedro Barata highlight real-world data understanding the metastatic prostate cancer setting, capturing data on patients treated for metastatic hormone-sensitive and then metastatic castration-resistant disease presented at ASCO GU 2022. Clinical trials presented over the past seven years have led to novel hormonal therapies as well as taxane based chemotherapy being approved for...

Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore

Details
Fred Saad, Bertrand Tombal, and Neal Shore join Alicia Morgans in a discussion on the results of the ARASENS trial which examined darolutamide in combination with docetaxel and ADT compared to docetaxel and ADT. They discuss the trial design, its endpoints, how it impacts practice in Canada, the US, and in Europe, and the ideal patient population for this treatment. Biographies: Neal Shore, MD, FA...

ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine publication on the international, phase 3 ARASENS trial. The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 2...

Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi

Details
Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...

Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne

Details
Thomas Keane is joined by Heather Payne to discuss the management of metastatic hormone-sensitive prostate cancer. While treatment with androgen deprivation therapy (ADT) provides initial responses, progression is common and a large proportion of prostate cancer-related deaths occur among men initially diagnosed with metastatic disease. Dr. Payne focuses her discussion on multiple trials determini...

Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal

Details
Neeraj Agarwal joins Alicia Morgans for a conversation on the TALAPRO-3 data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting. The TALAPRO-3 trial is a phase 3 trial assessing enzalutamide plus talazoparib versus placebo plus enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). They discuss how this trial fits into the l...

The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore

Details
Neal Shore joins Alicia Morgans to discuss his presentation from the American Urologic Association (AUA) annual meeting titled "Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer Patients Who Received Prior Anti androgen Therapy: PostHoc Analysis of ARCHES." This post hoc analysis aimed to evaluate the efficacy of enzalutamide + androgen deprivation therapy (ADT) versus placebo + ADT in...

Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi

Details
Alicia Morgans and Karim Fizazi discuss the recent analysis of the PEACE-1 study. The PEACE-1 study is a phase 3 trial evaluating abiraterone plus standard of care in M1 disease and local radiation therapy directed to the prostate primary. Dr. Fizazi discusses the study design and the first results he presented at ASCO 2021, specifically treatment with androgen deprivation therapy (ADT), docetaxel...

The Pattern of Metastatic Spread Impact on Efficacy of Enzalutamide - The ARCHES Study Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Efficacy of Enzalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: a Post Hoc Analyses of the ARCHES trial . The present study relies upon secondary analysis of the ARCHES trial, a multinational randomized controlled trial th...
email news signup